Adverse events following implantable cardioverter defibrillator implantation: A systematic review

Journal of Interventional Cardiac Electrophysiology

Volumn 40, Issue 2, 2014, Pages 191-205

  Persson, Rebecca ^a   Earley, Amy ^a   Garlitski, Ann C ^a   Balk, Ethan M ^a   Uhlig, Katrin ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Adverse events; Cardioverter defibrillator; Harms; Inappropriate shock; Prevention; Sudden cardiac death

Indexed keywords

ARTERIOVENOUS FISTULA; ARTICLE; CARDIAC PERFORATION; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DEEP PHLEBITIS; DEVICE INFECTION; ELECTRIC SHOCK; EMBOLISM; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HEART INJURY; HEART TAMPONADE; HEMATOMA; HEMATOTHORAX; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MEDICAL DEVICE COMPLICATION; PERFORATION; PERIPHERAL EMBOLISM; PERIPHERAL NERVE INJURY; PHLEBITIS; PNEUMOTHORAX; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SEX DIFFERENCE; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VALVULAR HEART DISEASE; AGED; COMORBIDITY; DEATH, SUDDEN, CARDIAC; DEVICE FAILURE; EPIDEMIOLOGY; FEMALE; INCIDENCE; INFECTION; MALE; META ANALYSIS; MIDDLE AGED; MORTALITY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT FAILURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAUSALITY; COMORBIDITY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; EQUIPMENT FAILURE; FEMALE; HOSPITAL MORTALITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMOTHORAX; PROSTHESIS-RELATED INFECTIONS; RISK FACTORS; SURVIVAL RATE; THROMBOSIS; TREATMENT FAILURE;

EID: 84905593518     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-014-9913-z     Document Type: Article

References (77)

1. Earley, A., Persson, R., Garlitski, A., Balk, E., & Uhlig, K. (2014). Effectiveness of implantable cardioverter defibrillators for primary prevention of sudden cardiac death in subgroups: a systematic review. Annals of Internal Medicine, 160, 111-121.
2. Bernard, M. L., Shotwell, M., Nietert, P. J., & Gold, M. R. (2012). Meta-analysis of bleeding complications associated with cardiac rhythm device implantation. Circulation. Arrhythmia and Electrophysiology, 5, 468-474.
3. Cheng, A., Wang, Y., Curtis, J. P., & Varosy, P. D. (2010). Acute lead dislodgements and in-hospital mortality in patients enrolled in the national cardiovascular data registry implantable cardioverter defibrillator registry. Journal of the American College of Cardiology, 56, 1651-1656.
4. Polin, G. M., Zado, E., Nayak, H., Cooper, J.M., Russo, A.M., Dixit, S., et al. (2006). Proper management of pericardial tamponade as a late complication of implantable cardiac device placement. American Journal of Cardiology, 98, 223-225. (Pubitemid 43975499)
5. Sohail, M. R., Henrikson, C. A., Braid-Forbes, M. J., Forbes, K. F.,& Lerner, D. J. (2011). Mortality and cost associated with cardiovascular implantable electronic device infections. Archives of Internal Medicine, 171, 1821-1828.
6. van Rees, J. B., de Bie, M. K., Thijssen, J., Borleffs, C. J., Schalij, M. J., & van Erven, L. (2011). Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. Journal of the American College of Cardiology, 58, 995-1000.
7. Borne, R. T., Varosy, P. D., & Masoudi, F. A. (2013). Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches. JAMA Internal Medicine, 173, 859-865.
8. Bostwick, J. M., & Sola, C. L. (2007). An updated review of implantable cardioverter/defibrillators, induced anxiety, and quality of life. The Psychiatric Clinics of North America, 30, 677-688.
9. Germano, J. J., Reynolds, M., Essebag, V., & Josephson, M. E. (2006). Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? American Journal of Cardiology, 97, 1255-1261.
10. Hauptman, P. J., Chibnall, J. T., Guild, C., & Armbrecht, E. S. (2013). Patient perceptions, physician communication, and the implantable cardioverter-defibrillator. JAMA Internal Medicine, 173, 571-577.
11. Matlock, D. D., Nowels, C. T., Masoudi, F. A., Sauer, W. H., Bekelman, D. B., Main, D. S., et al. (2011). Patient and cardiologist perceptions on decision making for implantable cardioverterdefibrillators: a qualitative study. Pacing and Clinical Electrophysiology, 34, 1634-1644.
12. Uhlig, K., Balk, E.M., Earley, A., Persson, R., Garlitski, A. C., Chen, M., et al. (2013). Assessment on implantable defibrillators and the evidence for primary prevention of sudden cardiac death. Evidence Report/Technology Assessment. (Prepared by the Tufts Evidence-based Practice Center under Contract No. 290-2007-10055-I.) Rockville: Agency for Healthcare Research and Quality. www.effectivehealthcare.gov/reports/final.cfm.
13. Hammill, S. C., Kremers, M. S., Kadish, A. H., Stevenson, L. W., Heidenreich, P. A., Lindsay, B. D., et al. (2009). Review of the ICD Registry's third year, expansion to include lead data and pediatric ICD procedures, and role for measuring performance. Heart Rhythm, 6, 1397-1401.
14. Wallace, B. C., Trikalinos, T. A., Lau, J., Brodley, C., & Schmid, C. H. (2010). Semi-automated screening of biomedical citations for systematic reviews. BMC Bioinformatics, 11, 55.
15. Chou, R., Aronson, N., Atkins, D., Ismaila, A. S., Santaguida, P., Smith, D. H., et al. (2010). AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. Journal of Clinical Epidemiology, 63, 502-512.
16. Santaguida, P., Raina, P., Ismaila, A. McMaster Quality Assessment Scale of Harms (McHarm) for primary studies, http://bmg.cochrane.org/sites/bmg. cochrane.org/files/uploads/McHarm%20for%20Primary%20Studies.pdf. Last accessed 8 Jan 2013.
17. Owens, D. K., Lohr, K. N., Atkins, D., Treadwell, J. R., Reston, J. T., Bass, E. B., et al. (2010). AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions - agency for healthcare research and quality and the effective healthcare program. Journal of Clinical Epidemiology, 63, 513-523.
18. Aggarwal, A., Wang, Y., Rumsfeld, J. S., Curtis, J. P., & Heidenreich, P. A. (2009). Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation. Heart Rhythm, 6, 1565-1571.
19. Curtis, J. P., Luebbert, J. J., Wang, Y., Rathore, S. S., Chen, J., Heidenreich, P. A., et al. (2009). Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA, 301, 1661-1670.
20. Dewland, T. A., Pellegrini, C. N., Wang, Y., Marcus, G. M., Keung, E., & Varosy, P. D. (2011). Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. Journal of the American College of Cardiology, 58, 1007-1013.
21. Freeman, J. V., Wang, Y., Curtis, J. P., Heidenreich, P. A., & Hlatky, M. A. (2010). The relation between hospital procedure volume and complications of cardioverter-defibrillator implantation from the implantable cardioverter-defibrillator registry. Journal of the American College of Cardiology, 56, 1133-1139.
22. Freeman, J. V., Wang, Y., Curtis, J. P., Heidenreich, P. A., & Hlatky, M. A. (2012). Physician procedure volume and complications of cardioverter-defibrillator implantation. Circulation, 125, 57-64.
23. Haines, D. E., Wang, Y., & Curtis, J. (2011). Implantable cardioverter-defibrillator registry risk score models for acute procedural complications or death after implantable cardioverter-defibrillator implantation. Circulation, 123, 2069-2076.
24. Peterson, P. N., Daugherty, S. L., Wang, Y., Vidaillet, H. J., Heidenreich, P. A., Curtis, J. P., et al. (2009). Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation, 119, 1078-1084.
25. Tsai, V., Goldstein, M. K., Hsia, H. H., Wang, Y., Curtis, J., & Heidenreich, P. A. (2011). Age differences in primary prevention implantable cardioverter-defibrillator use in U.S. individuals. Journal of American Geriatrics Society, 59, 1589-1595.
26. Tsai, V., Goldstein, M. K., Hsia, H. H., Wang, Y., Curtis, J., & Heidenreich, P. A. (2011). Influence of age on perioperative complications among patients undergoing implantable cardioverter-defibrillators for primary prevention in the United States. Circulation. Cardiovascular Quality and Outcomes, 4, 549-556.
27. Sengupta, J., Kendig, A. C., Goormastic, M., Hwang, E. S., Ching, E. A., Chung, R., et al. (2012). Implantable cardioverter-defibrillator FDA safety advisories: impact on patient mortality and morbidity. Heart Rhythm, 9, 1619-1626.
28. Lyman, S., Sedrakyan, A., Do, H., Razzano, R., & Mushlin, A. I. (2011). Infrequent physician use of implantable cardioverter-defibrillators risks patient safety. Heart, 97, 1655-1660.
29. Thijssen, J., Borleffs, C. J., van Rees, J. B., Man, S., de Bie, M. K., Venlet, J., et al. (2012). Implantable cardioverter-defibrillator longevity under clinical circumstances: an analysis according to device type, generation, and manufacturer. Heart Rhythm, 9, 513-519.
30. Tsai, F. S., Aronow, W. S., Devabhaktuni, S., Desai, H., Kruger, A., Lai, H. M., et al. (2010). Prevalence of complications during implantation and during 38-month follow-up of 1060 consecutive patients with implantable cardioverter-defibrillators. American Journal of Therapy, 17, e8-e10.
31. Varma, N., Michalski, J., Epstein, A. E., & Schweikert, R. (2010). Automatic remote monitoring of implantable cardioverter-defibrillator lead and generator performance: the Lumos-T Safely RedUceS RouTine Office Device Follow-Up (TRUST) trial. Circulation. Arrhythmia and Electrophysiology, 3, 428-436.
32. Landolina, M., Gasparini, M., Lunati, M., Iacopino, S., Boriani, G., Bonanno, C., et al. (2011). Long-term complications related to biventricular defibrillator implantation: rate of surgical revisions and impact on survival: insights from the Italian Clinical Service Database. Circulation, 123, 2526-2535.
33. Gradaus, R., Block, M., Brachmann, J., Breithardt, G., Huber, H. G., Jung, W., et al. (2003). Mortality, morbidity, and complications in 3344 patients with implantable cardioverter defibrillators: results fron the German ICD Registry EURID. Pacing and Clinical Electrophysiology, 26, t-8.
34. Porterfield, J. G., Porterfield, L. M., Kuck, K. H., Corbisiero, R., Greenberg, S. M., Hindricks, G., et al. (2010). Clinical performance of the St. Jude Medical Riata defibrillation lead in a large patient population. Journal of Cardiovascular Electrophysiology, 21, 551-556.
35. Dichtl, W., Wolber, T., Paoli, U., Brüllmann, S., Stühlinger, M., Berger, T., et al. (2011). Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients. Clinical Cardiology, 34, 433-436.
36. Bode, F., Himmel, F., Reppel, M., Mortensen, K., Schunkert, H., & Wiegand, U. K. (2012). Should all dysfunctional high-voltage leads be extracted? Results of a single-centre long-term registry. Europace, 14, 1764-1770.
37. Moss, A. J., Zareba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine, 346, 877-883. (Pubitemid 34984635)
38. Borleffs, C. J., van Erven, L., van Bommel, R. J., van der Velde, E. T., van der Wall, E. E., Bax, J. J., et al. (2009). Risk of failure of transvenous implantable cardioverter-defibrillator leads. Circulation. Arrhythmia and Electrophysiology, 2, 411-416.
39. Hauser, R. G., Mugglin, A. S., Friedman, P. A., Kramer, D. B., Kallinen, L., McGriff, D., et al. (2012). Early detection of an underperforming implantable cardiovascular device using an automated safety surveillance tool. Circulation. Cardiovascular Quality and Outcomes, 5, 189-196.
40. Morrison, T. B., Friedman, P. A., Kallinen, L. M., Hodge, D. O., Crusan, D., Kumar, K., et al. (2011). Impact of implanted recalled sprint Fidelis lead on patient mortality. Journal of the American College of Cardiology, 58, 278-283.
41. Parkash, R., Thibault, B., Sterns, L., Sapp, J., Krahn, A., Talajic, M., et al. (2012). Sprint Fidelis lead fractures in patients with cardiac resynchronization therapy devices: insight from the Resynchronization/ Defibrillation for Ambulatory Heart Failure (RAFT) study. Circulation, 126, 2928-2934.
42. van Rees, J. B., van Welsenes, G. H., Borleffs, C. J., Thijssen, J., van der Velde, E. T., van der Wall, E. E., et al. (2012). Update on smalldiameter implantable cardioverter-defibrillator leads performance. Pacing and Clinical Electrophysiology, 35, 652-658.
43. MacFadden, D. R., Crystal, E., Krahn, A. D., Mangat, I., Healey, J. S., Dorian, P., et al. (2012). Sex differences in implantable cardioverter- defibrillator outcomes: findings from a prospective defibrillator database. Annals of Internal Medicine, 156, 195-203.
44. Charytan, D. M., Patrick, A. R., Liu, J., Setoguchi, S., Herzog, C. A., Brookhart, M. A., et al. (2011). Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. American Journal of Kidney Diseases, 58, 409-417.
45. Brüllmann, S., Dichtl, W., Paoli, U., Haegeli, L., Schmied, C., Steffel, J., et al. (2012). Comparison of benefit and mortality of implantable cardioverter-defibrillator therapy in patients aged >=75 years versus those <75 years. American Journal of Cardiology, 109, 712-717.
46. Birnie, D. H., Parkash, R., Exner, D. V., Essebag, V., Healey, J. S., Verma, A., et al. (2012). Clinical predictors of Fidelis lead failure: report from the Canadian Heart Rhythm Society Device Committee. Circulation, 125, 1217-1225.
47. Cheung, J.W., Tobin-Hess, A., Patel, A., Slotwiner, D. J.,&Goldner, B. G. (2012). Trends in Fidelis lead survival: transition from an exponential to linear pattern of lead failure over time. Circulation. Arrhythmia and Electrophysiology, 5, 906-912.
48. Tzogias, L., Bellavia, D., Sharma, S., Donohue, T. J., & Schoenfeld, M. H. (2012). Natural history of the Sprint Fidelis lead: survival analysis from a large single-center study. Journal of Interventional Cardiac Electrophysiology, 34, 37-44.
49. Brumberg, G. E., Kaseer, B., Shah, H., Saba, S., & Jain, S. (2012). Biventricular defibrillator patients have higher complication rates after revision of recalled leads. Pacing and Clinical Electrophysiology, 35, 665-671.
50. de Bie, M. K., van Rees, J. B., Thijssen, J., Borleffs, C. J., Trines, S. A., Cannegieter, S. C., et al. (2012). Cardiac device infections are associated with a significant mortality risk. Heart Rhythm, 9, 494-498.
51. Remmelts, H. H., Meine, M., Loh, P., Hauer, R., Doevendans, P. A., van Herwerden, L. A., et al. (2009). Infection after ICD implantation: operating roomversus cardiac catheterisation laboratory. Netherlands Heart Journal, 17, 95-100.
52. Lee, D. S., Krahn, A.D., Healey, J. S., Birnie, D., Crystal, E., Dorian, P., et al. (2010). Evaluation of early complications related to de novo cardioverter defibrillator implantation insights from the Ontario ICD database. Journal of the American College of Cardiology, 55, 774-782.
53. Freudenberger, R. S., Hellkamp, A. S., Halperin, J. L., Poole, J., Anderson, J., Johnson, G., et al. (2007). Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation, 115, 2637-2641. (Pubitemid 46791362)
54. Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., et al. (2005). Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. New England Journal of Medicine, 352, 225-237. (Pubitemid 40110811)
55. Desai, H., Aronow, W. S., Ahn, C., Gandhi, K., Hussain, S., Lai, H. M., et al. (2010). Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure. American Journal of Cardiology, 105, 1336-1338.
56. Gold, M. R., Ahmad, S., Browne, K., Berg, K. C., Thackeray, L., & Berger, R. D. (2012). Prospective comparison of discrimination algorithms to prevent inappropriate ICD therapy: primary results of the Rhythm ID Going Head to Head Trial. Heart Rhythm, 9, 370-377.
57. Kleemann, T., Hochadel, M., Strauss, M., Skarlos, A., Seidl, K., & Zahn, R. (2012). Comparison between atrial fibrillation-triggered implantable cardioverter-defibrillator (ICD) shocks and inappropriate shocks caused by lead failure: different impact on prognosis in clinical practice. Journal of Cardiovascular Electrophysiology, 23, 735-740.
58. Larsen, P. D., De, S. P., Harding, S. A., Woodcock, E., & Lever, N.A. (2010). Use of implantable cardioverter defibrillators in the New Zealand context from 2000 to 2007. New Zealand Medical Journal, 123, 76-85.
59. Moss, A. J., Schuger, C., Beck, C. A., Brown, M.W., Cannom, D. S., Daubert, J. P., et al. (2012). Reduction in inappropriate therapy and mortality through ICD programming. New England Journal of Medicine, 367, 2275-2283.
60. Sandesara, C.M., Sullivan, R. M., Russo, A. M., Li, W., Kendig, A., Day, J. D., et al. (2011). Older persons with diabetes receive fewer inappropriate ICD shocks: results from the INTRINSIC RV trial. Journal of Cardiovascular Translational Research, 4, 27-34.
61. Saxon, L. A., Hayes, D. L., Gilliam, F. R., Heidenreich, P. A., Day, J., Seth, M., et al. (2010). Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation, 122, 2359-2367.
62. Schaer, B., Sticherling, C., Szili-Torok, T., Osswald, S., Jordaens, L., &Theuns, D. A. (2011). Impact of left ventricular ejection fraction on occurrence of ventricular events in defibrillator patients with coronary artery disease. Europace, 13, 1562-1567.
63. Sweeney, M. O., Sherfesee, L., DeGroot, P. J., Wathen, M. S., & Wilkoff, B. L. (2010). Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverterdefibrillator patients. Heart Rhythm, 7, 353-360.
64. van Welsenes, G. H., van Rees, J. B., Borleffs, C. J., Cannegieter, S. C., Bax, J. J., van Erven, L., et al. (2011). Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace, 13, 389-394.
65. Martin, D. T., McNitt, S., Nesto, R. W., Rutter, M. K., & Moss, A. J. (2011). Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT). Circulation. Heart Failure, 4, 332-338.
66. Sweeney, M. O., Sakaguchi, S., Simons, G., Machado, C., Connett, J. E., Yang, F., et al. (2012). Response to the Center for Medicare & Medicaid Services coverage with evidence development request for primary prevention implantable cardioverter-defibrillators: data from the OMNI study. Heart Rhythm, 9, 1058-1066.
67. van Rees, J. B., Borleffs, C. J., Thijssen, J., de Bie, M. K., van Erven, L., Cannegieter, S. C., et al. (2012). Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain. Europace, 14, 66-73.
68. Berenbom, L. D., Weiford, B. C., Vacek, J. L., Emert, M. P., Hall, W. J., Andrews, M. L., et al. (2005). Differences in outcomes between patients treated with single- versus dual-chamber implantable cardioverter defibrillators: a substudy of the Multicenter Automatic Defibrillator Implantation Trial II. Annals of Noninvasive Electrocardiology, 10, 429-435. (Pubitemid 43942702)
69. Sweeney, M. O., Wathen, M. S., Volosin, K., Abdalla, I., DeGroot, P. J., Otterness, M. F., et al. (2005). Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation, 111, 2898-2905. (Pubitemid 40814182)
70. van Rees, J. B., Borleffs, C. J., de Bie, M. K., Stijnen, T., van Erven, L., Bax, J. J., et al. (2011). Inappropriate implantable cardioverter- defibrillator shocks: incidence, predictors, and impact on mortality. Journal of the American College of Cardiology, 57, 556-562.
71. Wei, S., Loyo-Berríos, N. I., Haigney, M. C., Cheng, H., Pinnow, E. E., Mitchell, K. R., et al. (2011). Elevated B-type natriuretic peptide is associated with increased in-hospital mortality or cardiac arrest in patients undergoing implantable cardioverter-defibrillator implantation. Circulation. Cardiovascular Quality and Outcomes, 4, 346-354.
72. Peterson, P. N., Varosy, P. D., Heidenreich, P. A., Wang, Y., Dewland, T. A., Curtis, J. P., et al. (2013). Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. JAMA, 309, 2025-2034.
73. Resnic, F. S., & Normand, S. L. (2012). Postmarketing surveillance of medical devices - filling in the gaps. New England Journal of Medicine, 366, 875-877.
74. Hauser, R. G. (2012). Here we go again - failure of postmarketing device surveillance. New England Journal of Medicine, 366, 873-875.
75. Kremers, M. S., Hammill, S. C., Berul, C. I., Koutras, C., Curtis, J. S., Wang, Y., et al. (2013). The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm, 10, e59-e65.
76. Tan, V. H., Wilton, S. B., Kuriachan, V., Sumner, G. L., & Exner, D. V. (2014). Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. Circulation. Arrhythmia and Electrophysiology, 7(1), 164-170.
77. FDA approves first subcutaneous heart defibrillator. (2012). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321755.htm. Last accessed 8 Jan 2013.